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Introduction: Sclerostin (SOST), a soluble antagonist of Wnt signaling, is expressed in chondrocytes and contributes
to chondrocytes’ hypertrophic differentiation; however its role in osteoarthritis (OA) pathogenesis is not well known.
Based on our previous findings on the interaction between Wnt/β-catenin pathway and BMP-2 in OA, we aimed to
investigate the role of DNA methylation and BMP-2 on SOST’s expression in OA chondrocytes.
Methods: SOST mRNA and protein expression levels were investigated using real-time polymerase chain reaction
(PCR) and Western blot, respectively. The methylation status of SOST promoter was analysed using methylation-
specific PCR (MSP), quantitative methylation-specific PCR (qMSP) and bisulfite sequencing analysis. The effect of
BMP-2 and 5’-Aza-2-deoxycytidine (5-AzadC) on SOST’s expression levels were investigated and Smad1/5/8 binding
to SOST promoter was assessed by Chromatin Immunoprecipitation (ChΙP).
Results: We observed that SOST’s expression was upregulated in OA chondrocytes compared to normal. Moreover,
we found that the CpG region of SOST promoter was hypomethylated in OA chondrocytes and 5-AzadC treatment
in normal chondrocytes resulted in decreased SOST methylation, whereas its expression was upregulated. BMP-2
treatment in 5-AzadC-treated normal chondrocytes resulted in SOST upregulation, which was mediated through
Smad 1/5/8 binding on the CpG region of SOST promoter.
Conclusions: We report novel findings that DNA methylation regulates SOST’s expression in OA, by changing
Smad 1/5/8 binding affinity to SOST promoter, providing evidence that changes in DNA methylation pattern could
underlie changes in genes’ expression observed in OA.Introduction
Osteoarthritis (OA), a chronic degenerative disease of
the joints, is a major health burden linked to high
morbidity in the aging population [1, 2]. The central
pathological features of OA are the progressive degrad-
ation of articular cartilage, new bone formation at joint
margins (osteophytes) and changes in subchondral bone* Correspondence: atsezou@med.uth.gr
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creativecommons.org/publicdomain/zero/1.0/structure (sclerosis) [3]. OA is considered a multifactorial
disease and several risk factors contribute to its pathogen-
esis, including genetic predisposition, aging, obesity and
joint malignment [2, 4].
Articular chondrocytes may be the most important
cells that are involved in OA pathogenesis [5, 6]. The
disruption of matrix equilibrium between synthesis and
degradation of extracellular matrix (ECM) components
and progressive loss of cartilage tissue are associated with
changes in their anabolic and catabolic activities following
exposure to multiple signals [7, 8]. Recently, it was dem-
onstrated that one of the genes that are deregulated in OAccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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the SOST gene, is specifically expressed by osteocytes and
is involved in bone homeostasis [10, 11]. SOST is a soluble
antagonist of Wnt signaling [12] and it has been demon-
strated that SOST loss-of-function mutations cause ab-
normal skeletal phenotypes in humans, characterized by
high bone mineral density [13, 14], whereas transgenic
mice that overexpress SOST are osteopenic due to re-
duced bone formation [15]. In OA, which is character-
ized by new bone formation, it has been reported that
SOST is implicated in OA disease processes in both
bone and cartilage with opposing effects, by promoting
subchondral bone sclerosis while inhibiting cartilage
degradation [9].
Besides the well-known role of SOST as a Wnt signal-
ing inhibitor, it has been recently suggested that SOST
interacts with other signaling pathways, such as bone
morphogenic proteins (BMPs) and affects the biology of
the skeleton [16–18]. The canonical BMP-Smad pathway
induces human mesenchymal stem cells to differentiate
into chondrocytes and osteoblasts and BMP-2 is a
crucial local factor responsible for chondrocyte prolif-
eration and maturation during endochondral ossifica-
tion [19, 20]. Although the interaction between SOST
and BMPs is not yet clear, it has been shown that in
osteoblasts, SOST binds to BMPs and modulates the
activity of osteoblastic cells by reducing the expres-
sion of alkaline phosphatase (ALP), synthesis of type I
collagen, and mineralization [15]. Despite the role of
SOST as a Wnt and BMP signaling inhibitor, little is
known about its gene regulation. Previous studies
have reported that different molecular mechanisms
are able to modulate SOST expression, among which
BMPs and parathyroid hormone (PTH) [21–24].
Moreover, recent studies point towards the involve-
ment of DNA methylation in the regulation of SOST
expression in human osteocytes and bone cells [18,
25, 26]. In the present study, we sought to investigate
first whether DNA methylation regulates SOST ex-
pression in OA chondrocytes, and the role of BMP-2
on changes in SOST expression in OA.Materials and methods
Bioinformatic analysis
The 1,500 bp upstream of the SOST transcript start site
(TSS) were obtained from Ensembl genome browser and
putative CpG islands were identified using Metlyl Primer
Express software v1.0 (available from Applied Biosystems).
A CpG island was defined as a region of at least 200 bp,
with GC content greater than 50 %, and observed-to-
expected (O/E) CpG ratio >0.6 [27]. CpG islands were
tested for Smad binding sites (SBEs, 5’-GCCGnGCG-3’)
using ChIP bioinformatics tools.Patients and cartilage samples
Articular cartilage samples were obtained from femoral
condyles and tibial plateaus of 14 patients (11 female/3
male; mean age 67.8 ± 9.6 years) with primary hyper-
trophic OA, undergoing knee replacement surgery at the
Orthopaedics Department of the University Hospital of
Larissa. Radiographs were obtained before surgery and
graded using the Kellgren-Lawrence system according to
the following criteria: grade 1 (doubtful narrowing of
joint space and possible osteophytes), grade 2 (definite
osteophytes and possible narrowing of joint space), grade
3 (moderate multiple osteophytes, definite narrowing of
joint space and some sclerosis and possible deformity of
bone ends) and grade 4 (large osteophytes, marked nar-
rowing of joint space, severe sclerosis and definite deform-
ity of bone ends). All patients had a Kellgren-Lawrence
grade ≥3. The assessment of the radiographs by two inde-
pendent expert observers was blinded. Normal articular
cartilage was obtained from 10 individuals (7 female/3
male; mean age 56.9 ± 10.8 years), undergoing knee frac-
ture repair surgery, with no history of joint disease and
who did not show clinical manifestations compatible with
OA when specifically explored by radiography. Written in-
formed consent was obtained from all individuals in the
study. The study protocol conformed to the ethical guide-
lines of the 1975 Declaration of Helsinki as reflected in a
priori approval by the local ethical committee of the
University Hospital of Larissa.
Primary cultures of normal and OA human articular
chondrocytes
Articular cartilage was dissected and subjected to sequen-
tial digestion with 1 mg/ml pronase and 1 mg/ml collage-
nase P (Roche Applied Science, Mannheim, Germany).
Chondrocytes were counted and checked for viability
using trypan blue staining. More than 95 % of the cells
were viable after isolation. Isolated chondrocytes from in-
dividual specimens were separately cultured with DMEM/
F-12 (GIBCO, Life Technologies, Paisley, UK) plus 5 %
FBS (Invitrogen, Life Technologies, Paisley, UK) at 37 °C
under a humidified 5 % CO2 atmosphere until reaching
confluence for 4–6 days. Half of cultured chondrocytes
were then harvested by trypinization and were used for
DNA, RNA and protein extraction. The other half was
cultured again without treatment until confluence for 1
week (passage-1 chondrocytes).
Passage-1 normal and OA chondrocytes were seeded
on six-well plates at 3 × 105 cells/well and 3 days post-
seeding cells were treated with 50 ng/ml of BMP-2
(Sigma-Aldrich, MO, USA) for 24 and 48 h or with 5 μM
5-AzadC (Sigma-Aldrich) in dimethyl sulfoxide (DMSO).
Media containing DMSO or DMSO+5-AzadC was ex-
changed daily and lasted for 5 days. Moreover, for BMP-2
experiments, chondrocytes were treated with or without
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ml of BMP-2 was added for 48 h.
RNA extraction and quantification of mRNA expression
Total cellular RNA was extracted from cultured chondro-
cytes using Trizol reagent (Invitrogen, Life Technologies,
Paisley, UK). Preservation of 28S and 18S ribosomal RNA
(rRNA) species was used to assess RNA integrity. All the
samples included the study were with prominent 28S and
18S rRNA components. The yield was quantified spectro-
photometrically. Transcription of 1 μg RNA to cDNA was
performed using SuperScript III reverse transcriptase
(Invitrogen, Life Technologies, Paisley, UK) and random
primers (Invitrogen, Life Technologies, Paisley, UK).
Quantification of SOST mRNA expression was per-
formed by real-time PCR (ABI 7300, Applied Biosystems,
Foster, CA, USA). The oligonucleotide primers used for
SOST amplification are shown in Table 1. Reactions were
done in triplicate using 2 μl of cDNA per reaction. Real-
time PCR validation was carried out using the 2-ΔΔCT
method. Normalized gene expression values for each gene
based on cycle threshold (CT) values for each of the genes
and the housekeeping gene glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) were generated.
Protein extraction and western blot analysis
Chondrocytes were lysed using radioimmunoprecipitation
assay (RIPA) buffer containing 10 mM Tris (pH 7.5), 150
mM NaCl, 1 % Triton X-100, 1 % sodium deoxycholate,
0.1 % SDS, 1 mM EDTA, and a cocktail of protease inhibi-
tors. Protein concentration was quantified using the
Bio-Rad Bradford protein assay (Bio-Rad Protein Assay,
BioRad, Hercules, CA, USA) with bovine serum albumen
as standard. Cell lysates from chondrocytes were electro-
phoresed and separated on 12 % acrylamide gels and
transferred to PVDF membranes (Millipore, Billerica, MA,Table 1 Primer sequences for PCR, real-time PCR, methylation-
specific PCR (MSP), quantitative MSP (Qmsp) and bisulfite (Bis.)
sequencing analysis
Name Sequence (5′-3) Experiment
M-SOST-forward GAATAGGTCGGGTTTAGTTTC MSP, qMSP
M-SOST-reverse ACCTCCCACGTACTAACGA MSP, qMSP
U-SOST-forward GGAATAGGTTGGGTTTAGTTTT MSP, qMSP






Promoter SOST-reverse TGAGCTCCGGCTTTTAATTG PCR
BSP SOST-forward TTATTTGTTGGTGGGGTGATAA Bis. sequencing
BSP SOST-reverse ACAAAACCCAAACCTACTCTCC Bis. sequencingUSA). The membrane was probed with anti- SOST (1:100
dilution) (Novus biologicals, CO, USA) and signal was de-
tected using anti-rabbit immunoglobulin IgG conjugated
with horseradish peroxidase (1:10.000 dilution) (Invitro-
gen, Life Technologies, Paisley, UK). The results were nor-
malized using anti-β-actin polyclonal antibody (1:3.000
dilution) (Sigma-Aldrich, MO, USA). PVDF membranes
were then exposed to photographic film and western
blot bands from several different blots were quantified
using the NIH Scion Image according to the software
guidelines.
DNA methylation analysis by MSP
Genomic DNA was extracted from normal and OA cul-
tured chondrocytes using the Genomic DNA Isolation
Kit (Qiagen, Valencia, CA, USA) and was treated with
bisulfite conversion reagents using the MethylCode™
Bisulfite Conversion Kit (Invitrogen, Life Technologies,
Paisley, UK) according to the manufacturer’s instruction.
The region of interest in the SOST promoter was ampli-
fied by PCR using primers for MS-PCR derived from the
Methlyl Primer Express (software v1.0) (Table 1). PCR
reaction was confirmed by electrophoresis in a 3 % agar-
ose gel and was stained with ethidium bromide. Quanti-
fication analysis of bands was performed using the NIH
Scion Image according to the software guidelines.
DNA methylation analysis by qMSP
Quantitative methylation-specific PCR (qMSP) for the
CpG island of the SOST promoter was performed using
a real-time PCR instrument (ABI 7300, Applied Biosys-
tems, Foster, CA, USA). In the qMSP reaction, 2 μl of
bisulfite-treated genomic DNA were amplified with 2 ×
EpiTect Master Mix (Qiagen, Valencia, CA, USA) and
0,75 μΜ primers (Table 1) in a total volume of 25 μl.
Amplification conditions were: 95 °C for 5 minutes,
followed by 40 cycles of 95 °C for 10 s, 55 °C for 30 s,
and 72 °C for 27 s, with a final extension of 72 °C for 10
minutes. DNA methylation values were calculated by in-
terpolating the cycle threshold gap (CtU-CtM) in a
standard curve, conducted using mixtures of methylated
and unmethylated human control samples with 0 %, 10 %,
25 %, 50 %, 75 %, 90 % and 100 % methylated DNA
(Qiagen, Valencia, CA, USA).
Bisulfite DNA sequencing analysis
Bisulfite-treated DNA was amplified by PCR using
primers for BSP-PCR derived from the Methlyl Primer
Express (software v1.0) (Table 1).). In the PCR reaction,
2 μl of bisulfite-treated genomic DNA were amplified with
10 × PCR buffer, 400 μΜ dNTPs, 1 U of AmpliTaq Gold
DNA polymerase (Applied Biosystems, Foster, CA, USA)
and 0,5 μΜ of each primer in a total volume of 25 μl.
Amplification conditions were: 95 °C for 10 minutes,
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72 °C for 1 minute, with a final extension of 72 °C for 5
minutes. PCR products were cleaned using QIAquick
PCR Purification kit (Qiagen, Valencia, CA, USA) and
then were sequenced using a Bigdye terminator v3.1 cycle
sequencing kit (Applied Biosystems, Foster, CA, USA) and
analyzed on the ABI 3130 Genetic Analyzer (Applied Bio-
systems). Sequencing was performed using the forward
primer and the methylation percentage for each CpG site
in the CpG island was quantified by measuring the ratio
between peak height values of cytosine (C) and thymine
(T), yielding the basic equation for the methylation per-
centage to be (C/(C + T) *100) [28].
Chromatin immunoprecipitation (ChIP) assay
ChIP was performed using a ChIP assay kit (Upstate
USA, Inc., Charlottesville, VA, USA) on normal and OA
chondrocytes. Cell lysates were pre-cleared by incuba-
tion with G-Sepharose beads and were incubated with
monoclonal antibody Smad-1/5/8 (Cell signalling Tech-
nology, Boston, MA, USA) overnight at 4 °C. Antibody
human purified IgG was used as control (R&D Systems,
McKinley Place, MN, USA). The immunoprecipitated
DNAs were used for PCR amplification. The primers
were designed according to the nucleotide sequence of
SOST promoter and the PCR fragment covered 250–400
bp of the promoter. Table 1 shows the primer sets that
amplify the promoter region containing putative sites as
observed after bioinformatic analysis. The PCR products
were fractionated on 3 % agarose gels and were stained
with ethidium bromide. Quantification analysis of bands
was performed using the NIH Scion Image according to
the software guidelines.
Statistical analysis
Data were analyzed using the SPPS software 20. Statis-
tical significance was determined using Student’s t test
and a confidence level of 95 % (p <0.05).Fig. 1 SOST mRNA and protein expression levels in normal and osteoarthritis
normal (n = 10) and OA chondrocytes (n = 14). GAPDH was used for normali
b Representative western blot of SOST protein expression in cultured normal
expression normalized to β-actin in normal (n = 5) and OA chondrocytes (n =Results
SOST mRNA and protein expression levels are increased
in OA chondrocytes
Using real-time PCR, we found higher SOST mRNA ex-
pression levels in OA compared to normal chondrocytes
(p = 0.005) (Fig. 1a). SOST protein levels confirmed our
real-time PCR findings. Western blot analysis revealed
that SOST protein expression is elevated in OA chon-
drocytes compared to normal (p = 0.038) (Fig. 1b).
DNA methylation status of SOST promoter is different
between normal and OA chondrocytes
Taking into consideration recent reports that demon-
strated involvement of epigenetics in the regulation of
SOSTs expression, we tested whether the DNA methyla-
tion status of the SOST promoter is different between
normal and OA chondrocytes. Bioinformatic analysis re-
vealed the presence of two CpG islands surrounding the
TSS of the SOST gene. One CpG island was located
upstream of the TSS and the other within exon 1, down-
stream of the transcription start codon. We then tested
the CpG islands for the presence of transcription factors
binding sites and especially Smad binding sites, as we
wanted to investigate the role of BMP-2, mediated
through Smad proteins, on SOST expression. As we
found Smad binding sites only in the first CpG island lo-
cated upstream of the TSS in the region of the SOST pro-
moter, we investigated the methylation status of this CpG
island. This CpG island was identified between −516 bp
and −256 bp upstream of the TSS, as a region of DNA
spanning over 200 bp with a GC content over 50 %. Using
MSP technology, we evaluated the methylation status of
this region in genomic DNA isolated from normal and
OA chondrocytes. Our results showed a significant differ-
ence in the methylation status between normal and OA
chondrocytes in this CpG island located at the SOST pro-
moter (Fig. 2a). Moreover, analysis by qMSP demonstrated
that this CpG-rich region at the SOST promoter was(OA) chondrocytes. a Quantitative SOST mRNA expression in cultured
zation of the real-time PCR data (error bars = standard error, *p = 0.005).
and OA chondrocytes and a bar graph showing relative SOST protein
5) (error bars = standard error, *p = 0.038)
Fig. 2 DNA methylation status of the SOST promoter in normal and osteoarthritis (OA) chondrocytes. a DNA methylation status of CpG island
located upstream of the transcript start site (TSS) in the region of the SOST promoter in cultured normal (n = 10) and OA chondrocytes (n = 14)
(error bars = standard error, *p = 0.05 versus normal unmethylation status, **p = 0.043 versus normal methylation status). b DNA methylation
values in the CpG-rich region of the SOST promoter in cultured normal (n = 10) and OA chondrocytes (n = 10) by qMSP (error bars = standard
error, *p = 0.004). c Schematic representation of the CpG-rich region of the SOST promoter showing the six CpG sites that were analyzed using
the bisulfite DNA sequencing method. d The percentage of cytosine methylation of each CpG site located at the CpG region of the SOST
promoter in cultured normal (n = 5) and OA chondrocytes (n = 7), after bisulfite DNA sequencing analysis (error bars = standard error, *p = 0.05
and **p = 0.046)
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0,842) compared to OA chondrocytes (72,68 % ± 0,654)
(p = 0.004) (Fig. 2b). To identify the particular CpG sites
in this region whose methylation status is associated with
SOST expression, we analyzed six CpG dinucleotides inthe CpG island located at the SOST promoter using bisul-
fite DNA sequencing. We found that CpG sites 1, 4 and 6
were highly methylated (p = 0.05, p = 0.05 and p = 0.046,
respectively) in normal compared to OA chondrocytes
(Fig. 2c and d).
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modification of DNA methylation status
To confirm the causal inverse association between SOST
promoter methylation and gene expression, we evaluated
the ability of the demethylating agent 5-AzadC to pro-
mote SOST expression in chondrocytes. Normal chon-
drocytes, for which the promoter was found to be
methylated, were treated with 5-AzadC and subsequently
we evaluated SOST mRNA and protein levels by real-time
PCR and western blot analysis, respectively. We found
that SOST mRNA and protein levels (p = 0.041, p = 0.009,
respectively) were markedly increased in 5-AzadC-treated
cells compared to untreated (Fig. 3a, b) and this 5-AzadC-
induced change in gene expression was associated with a
decrease in DNA methylation in the CpG-rich region of
the SOST promoter (p = 0.032) (Fig. 3c, d).
DNA methylation contributes to regulation of SOST
expression by impairing the binding affinity of Smad 1/5/
8 transcription factors in its promoter
BMP-2 has been reported to play a significant role in the
regulation of SOST expression in bone. To gain insight
into the molecular mechanisms underlying SOST expres-
sion in OA chondrocytes, we examined the effect of BMP-
2 on SOST expression in normal and OA chondrocytes.
We found that BMP-2 treatment resulted in significant
induction of SOST expression in OA chondrocytes (p =Fig. 3 Effect of 5-AzadC treatment on SOST expression and DNA methylati
SOST mRNA expression in cultured normal chondrocytes (n = 3) after treat
real-time PCR data (error bars = standard error, *p = 0.041). b Representativ
after treatment with 5 μM 5-AzadC and a bar graph showing relative SOST
chondrocytes (n = 3) (error bars = standard error, *p = 0.009). c DNA methy
normal chondrocytes after treatment with 5 μM 5-AzadC. d DNA methylati
chondrocytes (n = 3) after treatment with 5 μM 5-AzadC by quantitative m0.004), but not in normal chondrocytes (Fig. 4a and b).
However, SOST expression levels were upregulated after
BMP-2 treatment in 5-AzadC-treated normal chondro-
cytes (Fig. 4c) (p = 0.001). To further investigate the intra-
cellular signaling pathway involved in BMP-2-induced
SOST expression, normal, OA, BMP-2 and/or 5-AzadC-
treated chondrocytes were subjected to ChIP assay using
an antibody against Smad-1/5/8 and we tested whether
Smads bind to the SOST promoter via Smad binding
elements. We found that the SOST promoter contains a
conserved Smad binding site in the CpG island located
upstream of the TSS and that Smad1/5/8 binding was en-
hanced in OA compared to normal chondrocytes (p =
0.05) and in BMP-2-treated OA compared to untreated
chondrocytes (p = 0.05) (Fig. 5a and c). Moreover, stron-
ger binding of Smad1/5/8 was observed in 5-AzadC-
treated normal chondrocytes compared to untreated
(Fig. 5b) (p = 0.05) and this affinity was significantly
increased in BMP-2/5-AzadC-treated normal chondro-
cytes compared to 5-AzadC-treated, BMP-2-treated and
untreated chondrocytes (Fig. 5d and e) (p = 0.05). No
difference was observed between BMP-2-treated and
untreated normal chondrocytes (Fig. 5c).
Discussion
SOST is a potent Wnt antagonist and a key regulator of
bone metabolism [9, 29]. OA is characterized by changeson status in the CpG-rich region of the SOST promoter. a Quantitative
ment with 5 μM 5-AzadC. GAPDH was used for normalization of the
e western blot of SOST protein levels in cultured normal chondrocytes
protein expression normalized to β-actin in 5-AzadC-treated normal
lation and unmethylation status of the SOST promoter in cultured
on values in CpG-rich region of the SOST promoter in cultured normal
ethylation-specific PCR (error bars = standard error, *p = 0.032)
Fig. 4 Effect of bone morphogenic protein 2 (BMP-2) and 5-AzadC treatment on SOST expression. a and b Efects of BMP-2 on SOST mRNA
expression levels in cultured normal (n = 3) and osteoarthritis (OA) chondrocytes (n = 3). Osteocalcin and LRP-5 used as positive controls that
upregulated by BMP-2 and LRP-6 and MMP-7 used as negative controls that not regulated by BMP-2(error bars = standard error, *p = 0.004).
c Detection of SOST mRNA expression levels by real time PCR after BMP-2 treatment in cultured normal chondrocytes (n = 3) with or without
5-AzadC. GAPDH was used for normalization of the real-time PCR data (error bars = standard error, *p = 0.001 versus control and DMSO/BMP-2
treatment). MMP matrix metalloproteinase, LRP low-density lipoprotein receptor-related protein
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the role of SOST in OA pathogenesis is not well known.
In the present study, we found that SOST is upregulated
in OA chondrocytes compared to normal, in agreement
with recent studies demonstrating that SOST is expressed
by articular chondrocytes and not only by bone cells in
end-stage OA [9, 30, 31]. However, Roudier et al. showed
that there is no difference in SOST expression between
normal and OA cartilage but a strong SOST staining only
in chondrocyte clusters that are often observed in
damaged OA articular cartilage [32]. Our results showed
an association between SOST expression and OA, how-
ever further investigation is necessary to determine
whether upregulation of SOST expression in OA chon-
drocytes is a causal factor in OA pathogenesis or a result
of the OA process.
It is known that DNA methylation patterns change
with increasing age and age-dependent hypomethylation
may contribute to pathological processes such as OA, an
age-related disease [33]. In an attempt to investigate therole of DNA methylation on SOST expression in OA,
we investigated the methylation status of the SOST gene
and observed, for the first time, that the SOST promoter
was hypermethylated in normal chondrocytes and hypo-
methylated in OA chondrocytes, suggesting the involve-
ment of epigenetic mechanisms in the regulation of
SOST expression in OA. However, additional functional
studies are needed to clarify whether these DNA methy-
lation changes in the SOST promoter are biologically
relevant. In general, changes in DNA methylation have
been shown to have an impact on OA pathology, as sev-
eral studies have demonstrated a different methylation
profile between OA and normal cartilage [34–36].
Further evidence for a relationship between DNA
methylation and gene expression was obtained after
treatment of chondrocytes with 5-AzadC, a potent in-
hibitor of DNA methylation. We found that 5-AzadC
treatment in normal chondrocytes resulted in upregula-
tion of SOST’s expression through altered methylation
status of the SOST promoter, suggesting that this region
Fig. 5 Occupancy of the SOST promoter by Smad1/5/8 by chromatin immunoprecipitation (ChIP) analysis. a Representative gel of Smad1/5/8
binding on the SOST promoter in cultured normal and osteoarthritis (OA) chondrocytes and densitometric analysis of the band intensity in
cultured normal (n = 3) and OA chondrocytes (n = 3) (error bars = standard error, *p = 0.05 versus normal chondrocytes). b Representative gel
of Smad1/5/8 binding on the SOST promoter in 5-AzadC- treated and untreated normal chondrocytes and densitometric analysis of the band
intensity in three different samples (n = 3) (error bars = standard error, *p = 0.05 versus control) c Representative gel of Smad1/5/8 binding on
the SOST promoter in bone morphogenic protein 2 (BMP-2)-treated and untreated normal and OA chondrocytes and densitometric analysis
of the band intensity in normal (n = 3) and OA samples (n = 3) (error bars = standard error, *p = 0.05 versus control, NS = not significant).
d Representative gel of Smad1/5/8 binding on the SOST promoter after BMP-2 treatment in cultured normal chondrocytes with or without
5-AzadC and densitometric analysis of the band intensity in three different samples (n = 3). (error bars = standard error, *p = 0.05 versus control
and #p = 0.05 versus BMP-2 treatment). Input chromatin used as positive control and IgG as negative control. e Representative gel of Smad1/5/8
binding on the SOST promoter after 5-AzadC treatment in cultured normal chondrocytes with or without BMP-2 and densitometric analysis of
the band intensity in three different samples (n = 3) (error bars = standard error, *p = 0.05 versus control, #p = 0.05 versus control and **p = 0.05
versus 5-AzadC treatment)
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cytes. Previous studies have demonstrated that DNA
methylation contributes to the regulation of SOST’s
expression in human osteocytes and bone cells [18, 25,
26, 37], suggesting a common molecular mechanism of
SOST gene expression in different cell types.
Besides DNA methylation, other factors, such as
growth factors and hormones can modulate SOST ex-
pression. BMP-2 is a growth factor which plays an im-
portant role in cartilage and bone homeostasis and it has
been demonstrated that BMP-2 contributes to the regu-
lation of SOST expression [16–18]. We found that treat-
ment with BMP-2 resulted in significant increase in
SOST expression in OA chondrocytes but not in normal.
However, SOST expression was upregulated after BMP-
2 treatment in 5-AzadC-treated normal chondrocytes,
suggesting that DNA methylation may impair the bind-
ing of transcriptional factors, especially Smad binding in
the SOST promoter. By using the ChIP assay, we demon-
strated the existence of a Smad binding site in the CpG
region located upstream of the TSS and found that the
binding affinity was decreased in the methylated pro-
moter, as the CpG dinucleotide, which were shown to be
methylated, were located at/or near the Smad binding
site. In addition, we observed that BMP-2 induced SOST
expression in 5-AzadC-treated normal chondrocytes,
which correlated with stronger binding affinity of Smads
in the SOST promoter, suggesting that ΒΜΡ-2 and the
methylation status of the SOST promoter regulate SOST
transcriptional levels. In a recent study, it was demon-
strated that BMPs stimulate SOST expression in human
bone cells by a mechanism involving BMPR1A receptor
and the downstream Smad-dependent pathway, suggest-
ing a direct influence of BMPs on SOST transcriptional
levels [18]. Moreover, Thillainadesan et al. showed an as-
sociation between DNA methylation status and Smad
binding, as they demonstrated that transforming growth
factor (TGF)-β signaling activation resulted in DNA de-
methylation of p15ink4b gene and subsequently increased
recruitment of SMAD2/3 on p15ink4b gene promoter [38].
SOST has become an attractive target for the treatment
of osteoporosis and other skeletal diseases associated with
low bone mineral density and increased fracture risk [31,
39]. Preclinical studies have demonstrated that antiscler-
ostin therapy results in increased bone formation and
bone mass in animal models [40–42]. Moreover, recent
human clinical trials with sclerostin-neutralizing monoclo-
nal antibody (Scl-Ab) therapy have shown beneficial
effects on bone formation and resorption markers in
healthy men and postmenopausal women [43]. However,
in OA the findings in preclinical studies using antiscleros-
tin therapy have been disappointing, as genetic absence of
sclerostin or antisclerostin therapy with monoclonal anti-
body had no impact on articular cartilage remodeling inanimals with age-dependent OA or post-traumatic OA,
respectively [32]. On the other hand, a recent study
showed that plasma and synovial fluid SOST levels are in-
versely associated with radiographic severity in knee OA,
suggesting SOST as a protective factor in OA and a pos-
sible biochemical marker of knee OA for reflecting the
degenerative process of primary knee OA [44]. Based on
the above reports and our results it can be suggested that
SOST may play a role in OA pathogenesis but its impact
on cartilage biology and extracellular matrix degradation
may be less powerful compared to its major regulatory
role in bone mass.
Conclusion
Our novel data strongly suggest that BMP-2 signaling
modulates SOST transcription in OA through changes in
Smad 1/5/8 binding affinity to the CpG region located
upstream of the TSS in the SOST gene, pointing towards
the involvement of DNA methylation in SOST expres-
sion in OA.
Abbreviations
5-AzadC: 5’-Aza-2-deoxycytidine; BMP-2: bone morphogenetic protein 2;
bp: base pairs; ChΙP: chromatin immunoprecipitation; DMEM/F-12:
Dulbecco’s Modified Eagles Medium/Ham’s F-12; FBS: fetal bovine serum;
GAPDH: glyceraldehyde 3-phosphate dehydrogenase; MSP: methylation-
specific polymerase chain reaction; OA: osteoarthritis; PCR: polymerase chain
reaction; qMSP: quantitative methylation-specific polymerase chain reaction;
SBE: Smad binding element; SOST: sclerostin; TSS: transcript start site.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
IP conceived of the study, designed and performed the experiments,
analysed the data and drafted the manuscript. FK participated in data
interpretation and helped to revise the manuscript. KNM participated in the
study design, provided cartilage samples and clinical evaluation of patients
and helped to draft the manuscript. AT conceived of the study, conducted
data analysis and results interpretation, and drafted and revised the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The present work was supported by the research financed project,
Epigenetic regulation in osteoarthritis through DNA methylation, from the
Hellenic Society of Orthopaedic Surgery and Traumatology.
Author details
1Laboratory of Cytogenetics and Molecular Genetics, University of Thessaly,
Faculty of Medicine, Biopolis, Larissa 41500, Greece. 2Department of
Orthopaedic Surgery, University of Thessaly, Faculty of Medicine, Biopolis,
Larissa 41500, Greece. 3Department of Biology, University of Thessaly, Faculty
of Medicine, Biopolis, Larissa 41500, Greece.
Received: 18 December 2014 Accepted: 5 June 2015
References
1. Suri P, Morgenroth DC, Hunter DJ. Epidemiology of osteoarthritis and
associated comorbidities. Pm R. 2012;4:10–9.
2. Johnson VL, Hunter DJ. The epidemiology of osteoarthritis. Best Pract Res
Clin Rheumatol. 2014;28:5–15.
3. Hunter DJ, Felson DT. Osteoarthritis. BMJ. 2006;332:639–42.
Papathanasiou et al. Arthritis Research & Therapy  (2015) 17:160 Page 10 of 104. Bertrand J, Cromme C, Umlauf D, Frank S, Pap T. Molecular mechanisms
of cartilage remodelling in osteoarthritis. Int J Biochem Cell Biol.
2010;42:1594–601.
5. Tchetina EV. Developmental mechanisms in articular cartilage degradation
in osteoarthritis. Arthritis. 2011;2011:683970.
6. Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the
pathogenesis of osteoarthritis. Ann NY Acad Sci. 2010;1192:230–7.
7. Roach HI, Aigner T. DNA methylation in osteoarthritic chondrocytes: a new
molecular target. Osteoarthritis Cartilage. 2007;15:128–37.
8. Goldring MB. Chondrogenesis, chondrocyte differentiation, and articular
cartilage metabolism in health and osteoarthritis. Ther Adv Musculoskelet
Dis. 2012;4:269–85.
9. Chan BY, Fuller ES, Russell AK, Smith SM, Smith MM, Jackson MT, et al.
Increased chondrocyte sclerostin may protect against cartilage degradation
in osteoarthritis. Osteoarthritis Cartilage. 2011;19:874–85.
10. Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, et al.
Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte
differentiation and regulates mineralization through a MEPE-ASARM-
dependent mechanism. J Bone Miner Res. 2011;26:1425–36.
11. Li F, Song N, Tombran-Tink J, Niyibizi C. Pigment epithelium derived factor
suppresses expression of Sost/sclerostin by osteocytes: Implication for its
role in bone matrix mineralization. J Cell Physiol. 2014;230:1243–9.
12. Blom AB, van Lent PL, van der Kraan PM, van den Berg WB. To seek shelter
from the WNT in osteoarthritis? WNT-signaling as a target for osteoarthritis
therapy. Curr Drug Targets. 2010;11:620–9.
13. Piters E, Culha C, Moester M, Van Bezooijen R, Adriaensen D, Mueller T, et al.
First missense mutation in the SOST gene causing sclerosteosis by loss of
sclerostin function. Hum Mutat. 2010;31:E1526–43.
14. Bhadada SK, Rastogi A, Steenackers E, Boudin E, Arya A, Dhiman V, et al.
Novel SOST gene mutation in a sclerosteosis patient and her parents. Bone.
2013;52:707–10.
15. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, et al.
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
EMBO J. 2003;22:6267–76.
16. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL. Sclerostin: current
knowledge and future perspectives. Calcif Tissue Int. 2010;87:99–107.
17. Paszty C, Turner CH, Robinson MK. Sclerostin: a gem from the genome
leads to bone-building antibodies. J Bone Miner Res. 2010;25:1897–904.
18. Delgado-Calle J, Arozamena J, Perez-Lopez J, Bolado-Carrancio A, Sanudo C,
Agudo G, et al. Role of BMPs in the regulation of sclerostin as revealed by
an epigenetic modifier of human bone cells. Mol Cell Endocrinol.
2013;369:27–34.
19. Steinert AF, Proffen B, Kunz M, Hendrich C, Ghivizzani SC, Noth U, et al.
Hypertrophy is induced during the in vitro chondrogenic differentiation of
human mesenchymal stem cells by bone morphogenetic protein-2 and
bone morphogenetic protein-4 gene transfer. Arthritis Res Ther.
2009;11:R148.
20. Shu B, Zhang M, Xie R, Wang M, Jin H, Hou W, et al. BMP2, but not BMP4, is
crucial for chondrocyte proliferation and maturation during endochondral
bone development. J Cell Sci. 2011;124:3428–40.
21. Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, et al. Control
of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone
Miner Res. 2007;22:1957–67.
22. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone.
2005;37:148–58.
23. Kamiya N, Kobayashi T, Mochida Y, Yu PB, Yamauchi M, Kronenberg HM,
et al. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP
signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone
Miner Res. 2010;25:200–10.
24. Perez-Campo FM, Sanudo C, Delgado-Calle J, Arozamena J, Zarrabeitia MT,
Riancho JA. A Sclerostin super-producer cell line derived from the human
cell line SaOS-2: a new tool for the study of the molecular mechanisms
driving Sclerostin expression. Calcif Tissue Int. 2014;95:194–9.
25. Delgado-Calle J, Sanudo C, Bolado A, Fernandez AF, Arozamena J,
Pascual-Carra MA, et al. DNA methylation contributes to the regulation
of sclerostin expression in human osteocytes. J Bone Miner Res.
2012;27:926–37.
26. Reppe S, Noer A, Grimholt RM, Halldorsson BV, Medina-Gomez C, Gautvik
VT, et al. Methylation of bone SOST, its mRNA, and serum sclerostin levels
correlate strongly with fracture risk in postmenopausal women. J Bone
Miner Res. 2015;30:249–56.27. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol
Biol. 1987;196:261–82.
28. Parrish RR, Day JJ, Lubin FD. Direct bisulfite sequencing for examination of
DNA methylation with gene and nucleotide resolution from brain tissues.
Curr Protoc Neurosci. 2012: Chapter 7:Unit 7 24.
29. Honasoge M, Rao AD, Rao SD. Sclerostin: recent advances and clinical
implications. Curr Opin Endocrinol Diabetes Obes. 2014;21:437–46.
30. Karlsson C, Dehne T, Lindahl A, Brittberg M, Pruss A, Sittinger M, et al.
Genome-wide expression profiling reveals new candidate genes associated
with osteoarthritis. Osteoarthritis Cartilage. 2010;18:581–92.
31. Lewiecki EM. Role of sclerostin in bone and cartilage and its potential as a
therapeutic target in bone diseases. Ther Adv Musculoskelet Dis. 2014;6:48–57.
32. Roudier M, Li X, Niu QT, Pacheco E, Pretorius JK, Graham K, et al. Sclerostin
is expressed in articular cartilage but loss or inhibition does not affect
cartilage remodeling during aging or following mechanical injury. Arthritis
Rheum. 2013;65:721–31.
33. Richardson B. Impact of aging on DNA methylation. Ageing Res Rev.
2003;2:245–61.
34. Rushton MD, Reynard LN, Barter MJ, Refaie R, Rankin KS, Young DA, et al.
Characterization of the cartilage DNA methylome in knee and hip
osteoarthritis. Arthritis Rheumatol. 2014;66:2450–60.
35. Jeffries MA, Donica M, Baker LW, Stevenson ME, Annan AC, Humphrey MB,
et al. Genome-wide DNA methylation study identifies significant epigenomic
changes in osteoarthritic cartilage. Arthritis Rheumatol. 2014;66:2804–15.
36. Moazedi-Fuerst FC, Hofner M, Gruber G, Weinhaeusel A, Stradner MH,
Angerer H, et al. Epigenetic differences in human cartilage between mild
and severe OA. J Orthop Res. 2014;32:1636–45.
37. Delgado-Calle J, Riancho JA, Klein-Nulend J. Nitric oxide is involved in the
down-regulation of SOST expression induced by mechanical loading. Calcif
Tissue Int. 2013;94:414–22.
38. Thillainadesan G, Chitilian JM, Isovic M, Ablack JN, Mymryk JS, Tini M, et al.
TGF-beta-dependent active demethylation and expression of the p15ink4b
tumor suppressor are impaired by the ZNF217/CoREST complex. Mol Cell.
2012;46:636–49.
39. Clarke BL. Anti-sclerostin antibodies: Utility in treatment of osteoporosis.
Maturitas. 2014;78:199–204.
40. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, et al. Sclerostin
antibody treatment increases bone formation, bone mass, and bone
strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res.
2009;24:578–88.
41. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, et al.
Two doses of sclerostin antibody in cynomolgus monkeys increases bone
formation, bone mineral density, and bone strength. J Bone Miner Res.
2010;25:948–59.
42. Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P. Sclerostin antibody
treatment enhances metaphyseal bone healing in rats. J Bone Miner Res.
2010;25:2412–8.
43. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled,
randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner
Res. 2011;26:19–26.
44. Mabey T, Honsawek S, Tanavalee A, Wilairatana V, Yuktanandana P, Saetan
N, et al. Plasma and synovial fluid sclerostin are inversely associated with
radiographic severity of knee osteoarthritis. Clin Biochem. 2014;47:547–51.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
